HOME > TOP STORIES

TOP STORIES

REGULATORY MHLW, US FDA to Exchange Information with a View to Standardizing Review Guidelines for Regenerative Medicines

July 17, 2013
REGULATORY Health Ministry to Set Up Committee on Diovan Studies, Compile Preventive Measures for Clinical Data Manipulation

July 16, 2013
REGULATORY MHLW Presses Kyoto Prefectural University of Medicine to Carry on Diovan Probe

July 16, 2013
ACADEMIA “Data Manipulated” in KYOTO Heart Study: Univ. Probe

July 12, 2013
ORGANIZATION JPWA Sets Up New Committee on Consumption Tax, NHI Drug Pricing Issues

July 12, 2013
BUSINESS Drug Makers to Disclose Payment Information This Summer Based on Transparency Guidelines

July 11, 2013
BUSINESS Blood Derivative Titan CSL Set to Beef Up Japan Biz with New Products

July 10, 2013
REGULATORY TPP Member States to Brief Japan on Drug Pricing, Intellectual Property on July 25

July 9, 2013
ORGANIZATION JSGM Officially Announces Unified Brand Name Plan for Generic Combination Drugs; 1st Single Name to Be Given to Preminent

July 8, 2013
ORGANIZATION JSGM Working to Build Consensus on Unified Brand Names for Generic Combination Drugs

July 5, 2013
ACADEMIA “No Data Manipulation” in VART Study of Diovan: Interim Report of Japanese Society of Hypertension

July 4, 2013
REGULATORY Notification Calls for Simultaneous Filing of Applications for Companion Diagnostics and Drugs

July 3, 2013
BUSINESS Japanese Society of Chemotherapy Joins Hands with Pharmas, Govt to Spur New Antibiotic Development

July 2, 2013
ORGANIZATION JMA Sets Up Pharmaceutical Affairs Section

July 1, 2013
BUSINESS Bayer Yakuhin to Shift Resources to Innovative New Drugs: President Brunn

June 28, 2013
ACADEMIA NHO Attains 30% Volume-Based Generic Target in FY2012

June 28, 2013
REGULATORY MHLW Maps Out New Vision for Pharma Industry; Research-Based Makers Will See “Survival of the Fittest,” It Says

June 27, 2013
BUSINESS Eisai to Suspend Sales of Future Mainstay Antiepileptic Drug in Germany

June 26, 2013
BUSINESS Filgrastim Biosimilars: Overseas Track Record vs. “Purely Made-in-Japan” Label

June 25, 2013
ACADEMIA Makers Should Venture into Drug Development Using iPS, CiRA Adviser Asonuma Says

June 25, 2013

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…